01

ABBVIE

U.S.A

Pharmtech & Ingredients

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-11-09

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 9139536

Drug Substance Claim :

Drug Product Claim :

Application Number : 208624

Patent Use Code : U-1753

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2028-11-09

Product Web Link

Corporate PDF

02

ABBVIE

U.S.A

Pharmtech & Ingredients

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-04-10

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 9044480

Drug Substance Claim :

Drug Product Claim :

Application Number : 208624

Patent Use Code : U-1638

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2031-04-10

Product Web Link

Corporate PDF

03

ABBVIE

U.S.A

Pharmtech & Ingredients

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-09-04

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 8466159

Drug Substance Claim :

Drug Product Claim :

Application Number : 208624

Patent Use Code : U-1637

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2032-09-04

Product Web Link

Corporate PDF

04

ABBVIE

U.S.A

Pharmtech & Ingredients

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-06-10

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 9006387

Drug Substance Claim :

Drug Product Claim :

Application Number : 208624

Patent Use Code : U-1687

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2030-06-10

Product Web Link

Corporate PDF

05

ABBVIE

U.S.A

Pharmtech & Ingredients

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-09-17

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 8501238

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 208624

Patent Use Code : U-1636

Patent Use Description : USE OF DASABUVIR TO IN...

Patent Expiration Date : 2028-09-17

Product Web Link

Corporate PDF

06

ABBVIE

U.S.A

Pharmtech & Ingredients

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-09-10

OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 8642538

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 207931

Patent Use Code : U-1638

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2029-09-10

Product Web Link

Corporate PDF

07

ABBVIE

U.S.A

Pharmtech & Ingredients

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-04-10

OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 9044480

Drug Substance Claim :

Drug Product Claim :

Application Number : 207931

Patent Use Code : U-1638

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2031-04-10

Product Web Link

Corporate PDF

08

ABBVIE

U.S.A

Pharmtech & Ingredients

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-06-10

OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 9006387

Drug Substance Claim :

Drug Product Claim :

Application Number : 207931

Patent Use Code : U-1687

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2030-06-10

Product Web Link

Corporate PDF

09

ABBVIE

U.S.A

Pharmtech & Ingredients

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2035-01-02

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 9333204

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 208624

Patent Use Code : U-1889

Patent Use Description :

Patent Expiration Date : 2035-01-02

Product Web Link

Corporate PDF

10

ABBVIE

U.S.A

Pharmtech & Ingredients

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-09-10

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

US Patent Number : 8642538

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 208624

Patent Use Code : U-1638

Patent Use Description : TREATMENT OF HCV INFEC...

Patent Expiration Date : 2029-09-10

Product Web Link

Corporate PDF

Ritonavir

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

45 API Suppliers

24 USDMF

11 CEP/COS

9 EU WC

3 KDMF

10 NDC API

22 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

62 Drugs in Development

INTERMEDIATES

5 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

107 FDF Dossiers

41 FDA Orange Book

18 Europe

7 Canada

1 Australia

25 South Africa

15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 100MG;25MG

TABLET;ORAL - 200MG;50MG

TABLET;ORAL - 100MG

RELATED EXCIPIENT COMPANIES

1 Minakem

3 Rochem International Inc

1 SPI Pharma

1 Seqens

8 DKSH

2 Jai Radhe Sales

1 PMC Isochem

1 Pharm-RX Chemical

2 Faran Shimi Pharmaceutical

6 Boai NKY Pharmaceuticals Ltd

1 Chynops Pharma

5 Gangwal Healthcare

8 Nanjing Well Pharmaceutical

4 ACG Worldwide

7 Actylis

1 Aeon Procare

2 Alcedo Pharmachem

3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

17 BASF

2 Bioplus Life Sciences

1 Clariant

12 Corel Pharma Chem

1 Finar

13 Gangwal Chemicals

1 Huzhou Sunflower Pharmaceutical

6 Ideal Cures Pvt Ltd

14 Kerry

3 Kima Chemical

6 Lonza Capsugel

4 Microlex e.U

2 Nanjing Bold Chemical

1 NEWEDGE Overseas

4 Novo Excipients

2 Pharmatrans-Sanaq

3 Pluviaendo

1 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

3 Roquette

15 Seppic

2 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

2 Sigachi Industries

2 The Dow Chemical Company

1 Ulanqab Kema New Material

2 Valens Pharmachem

TABLET;ORAL - 12.5MG;75MG;50MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - 100MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons